Critical Pharmaceuticals
HomeCompany ProfileNewsTechnologyManagement TeamPipelineEventsContact Us

Latest News

14th October 2009
  Critical Pharmaceuticals Secures £1.5m From Wellcome Trust To Develop hGH Nasal Spray
27th January 2009
  Global Health Ventures and Critical Sign Memorandum of Understanding for an Anti-Obesity Drug
10th November 2008
  Critical Pharmaceuticals Raise £650K
1st October 2008
  Critical Pharmaceuticals Enter Sustained Release hGH Arena
Technology
 

Technology

Critical Pharmaceuticals uses its supercritical fluid technologies to encapsulate drugs within biodegradable polymers for controlled release applications. In a low temperature, single step, solvent free process we can make injectable microparticles, implants and fibrous materials that constantly release the drug over weeks to months.

 

 
 

 

Videos

The movie on the right shows CO2 reaching and passing through its critical point (31°C / 74bar). Notice as the CO2 becomes supercritical the meniscus disappears, indicating there is no longer a distinction between liquid and gas. The meniscus returns as it is taken back below the critical point.

The second movie shows what effect supercritical CO2 has on PLGA (a polymer approved by the regulatory agencies for drug delivery). As you will see, as the CO2 becomes supercritical, the polymer liquefies.

The next movie shows a short burst of atomisation of a polymer/drug mixture. By careful nozzle selection and control of the atomisation environment, we can control particle formation.

  Reproduced with kind permission from the University of Nottingham.